Alpha Cognition Inc ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

NDAQ:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by XeniaTechieon Oct 12, 2021 1:40pm

137 Views

Post# 33997984

ACOG CEO presenting Oct 12 at 3 PM ET at LD Micro Main event

Still time to attend the LD Micro Main Event where $ACOG CEO will present an overview of the company's business and highlighting their lead asset - Alpha-1062 and it's early-stage asset Alpha-0602. Oct 12 at 3 PM ET (Check track 3 on the calendar) https://me21.mysequire.com/

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks